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Abstract: Classical resistance classifications (multidrug resistance [MDR], extensive drug resistance 
[XDR], pan-drug resistance [PDR]) are very useful for epidemiological purposes, however, they 
may not correlate well with clinical outcomes, therefore, several novel classification criteria (e.g., 
usual drug resistance [UDR], difficult-to-treat resistance [DTR]) were introduced for 
Gram-negative bacteria in recent years. Microbiological and resistance data was collected for 
urinary tract infections (UTIs) retrospectively, corresponding to the 2008.01.01–2017.12.31. period. 
Isolates were classified into various resistance categories (wild type/susceptible, UDR, MDR, XDR, 
DTR and PDR), in addition, two new indicators (modified DTR; mDTR and mcDTR) and a 
predictive composite score (pMAR) were introduced. Results: n = 16,240 (76.8%) outpatient and n = 
13,386 (69.3%) inpatient UTI isolates were relevant to our analysis. Citrobacter-Enterobacter-Serratia 
had the highest level of UDR isolates (88.9%), the Proteus-Providencia-Morganella group had the 
highest mDTR levels. MDR levels were highest in Acinetobacter spp. (9.7%) and 
Proteus-Providencia-Morganella (9.1%). XDR- and DTR-levels were higher in non-fermenters (XDR: 
1.7%–4.7%. DTR: 7.3%–7.9%) than in Enterobacterales isolates (XDR: 0%–0.1%. DTR: 0.02%–1.5%). 
Conclusions: The introduction of DTR (and its’ modifications detailed in this study) to the bedside 
and in clinical practice will definitely lead to substantial benefits in the assessment of the 
significance of bacterial resistance in human therapeutics.  
Keywords: clinical microbiology; indicators; urinary tract infection; Gram-negative; drug 
resistance; usual drug resistance; difficult-to-treat resistance; UDR; DTR; MDR; XDR; PDR 
 
1. Introduction 
The emergence and worldwide spread of antibiotic-resistant bacterial pathogens is one of the 
most serious concerns for modern medicine and a major public health issue, which requires 
participation of all the relevant stakeholders on a global scale [1–5]. Infections caused by drug 
resistant bacteria are associated with decreased quality of life (QoL) in the affected patients, 
increased costs for the healthcare infrastructure, the necessity to use antibiotics that are more 
expensive or have a disadvantageous toxicity profile and an increased mortality rate overall [6–8]. 
To make matters worse, the pipeline in the field of antibiotic discovery and the development of 
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novel agents is plagued by a strong disincentive for drug developers, as the return-on-investment 
for these drugs pales in comparison to other drugs for the therapy of chronic non-communicable 
diseases or cancer [9,10]. Although in recent years, so-called public-private partnerships (including 
the 10 × 20 Initiative of the US Food and Drug Administration and the New Drugs 4 Bad Bugs [ND4BB] 
programme of the European Medicines Agency) have tried to make the field of antimicrobial 
discovery an attractive field of investment for pharmaceutical companies, it is a far cry from the 
golden age of antibiotic discovery (1960–1980), when new drugs continuously appeared on the 
market [11–13]. Some reports have gone as far as to suggesting that mortality due to drug resistant 
pathogens will be one of the leading causes of death by 2050, surpassing the mortality rate of 
malignant illnesses [14]. 
If overall mortality and their economic impact is taken into consideration, the group of 
“ESKAPE” pathogens, namely E: Enterococcus faecium, S: Staphylococcus aureus or recently 
Stenotrophomonas maltophilia, K: Klebsiella pneumoniae or recently C: Clostridioides difficile, A: 
Acinetobacter baumannii, P: Pseudomonas aeruginosa, E: Enterobacter spp., or recently Enterobacteriaceae) 
present the most clinical challenges [15,16]. A plethora of resistance mechanisms has been described 
in various bacterial species; some of these resistance mechanisms are plasmid-mediated, which 
allows for their widespread dissemination and outbreak-formation (particularly in Gram-negative 
bacteria; e.g., transmission of carbapenemase genes), while some bacteria possess intrinsic resistance 
mechanisms present in all species (e.g., resistance to tetracyclines, nitrofurantoin and polymyxin B in 
Proteus, Providencia and Morganella species) [17–20]. During susceptibility-testing and choosing the 
appropriate therapy, both clinicians and clinical microbiologists need to be aware of intrinsic 
resistance and local developments in acquired resistance levels [21].  
As the clinical problem of bacterial drug resistance has emerged, several methods were 
developed to classify bacterial species into resistance categories; however, due to differences in these 
classifications, notable inconsistencies occurred in the reporting of epidemiological and clinical 
results [22]. The first global consensus criteria for the classification of drug resistance levels in 
bacteria were outlined by the collaborative efforts of the US Centers for Disease Control and 
Prevention (CDC) and the European Centre for Disease Control and Prevention (ECDC), namely the 
definitions for multidrug resistance (MDR), extensive drug resistance (XDR) and pan-drug 
resistance (PDR) [23]. These resistance categories are useful in reporting epidemiological data for the 
assessment of the resistance situation is a given geographical region. However, this categorization of 
resistance does not take into account the differences in the clinical utility and pharmacological 
features of the individual drugs tested; these characteristics may significantly alter the clinical 
outcomes [24]. This was highlighted by several reports, where they concluded that an infection with 
an MDR pathogen alone (without taking into consideration the drugs used for therapy) is not 
associated with an increased mortality rate, while the use of antibiotics with pronounced toxicities 
(e.g., colistin in monotherapy or combination therapy) carries a risk of excess mortality [25–27]. In 
the recent years, several novel classification criteria for bacterial resistance were published, with the 
aim of improving the correlation between resistance data and clinical outcomes: multiple antibiotic 
resistance (MAR) index [28,29], usual drug resistance (UDR; a definition created by McDonell et al. 
in 2016, defining resistance which may still be effectively treated with first-line drugs; first used in 
the context of clinical trials involving novel antibiotics [30,31]) and difficult-to-treat resistance (DTR; 
a definition created by Kadri et al. in 2018, highlighting resistance to first-line antibiotics with low 
toxicity; first used in the context of Gram-negative bloodstream infections [24]).  
From the context of human medicine, urinary tract infections (UTIs) are the second most 
common infections in developed countries, representing an important factor of morbidity and 
mortality, both among outpatients and hospitalized patients (corresponding to 20%–60% of 
infections overall) [32,33]. In addition, UTIs are a sizable economic burden for healthcare institutions 
and national economies: their substantial economic impact is attributable to their pharmacological 
therapy, hospital costs and lost working days due to recovery; the economic losses caused by UTIs 
have been estimated to be around three billion US dollars [34]. The most common causes of UTIs in 
both community and nosocomial settings are Gram-negative bacteria; members of the 
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Enterobacterales order are the most prevalent (E. coli is the considered the as principal etiological 
agent, however, the relevance of other members of the order should not be underestimated) 
causative pathogens, nevertheless, there is an increasing appreciation for the pathogenic role of 
non-fermenting Gram-negative bacteria (NFGNB; with Acinetobacter spp. and P. aeruginosa having 
the highest relevance) in UTIs, especially in patients with predisposing factors for development of 
complicated UTIs [35,36].  
Even though the mortality rate associated with UTIs caused by Gram-negative bacteria falls 
below the mortality of bloodstream infections caused by the same pathogens, due to their high 
prevalence and constant developments in resistance levels, these infections may be considered as an 
important target for antibiotic resistance surveillance and stewardship interventions [37]. The 
epidemiology and patient characteristics of UTIs in our local setting (Albert Szent-Györgyi Clinical 
Center; Szeged, Hungary) has been extensively characterized previously [20,38–41]. The aim of the 
present study was to report on the resistance levels in Gram-negative UTI pathogens in the same 
healthcare setting retrospectively, using existing and novel classifications of bacterial resistance 
(which were not previously used in UTIs), over a 10-year study period (2008–2017). In addition, the 
study aims to introduce novel indicators of resistance, which may be useful in the characterization of 
resistance in UTIs in the future. 
2. Materials and Methods  
2.1. Study Design, Data Collection 
In the present study, microbiological and resistance data was collected retrospectively, 
corresponding to the time period between 1 January 2008 and 31 December 2017 (10 years) at the 
Institute of Clinical Microbiology, University of Szeged. The Institute is the primary diagnostic 
laboratory of the Albert Szent-Györgyi Clinical Center, which is a primary- and tertiary-care 
teaching hospital in the Southern Great Plain of Hungary (serving as a specialized healthcare center 
to about 600,000 people, based on the most recent census data) [42]. The collection of the data used in 
this study was performed manually, in the records of the Institute’s laboratory information system 
(LIS), corresponding to urine samples positive for Gram-negative pathogens included in this study. 
Samples where bacterial colony counts were deemed clinically significant (>105 CFU/mL; however, 
this was subject to interpretation by the senior clinical microbiologists at the time of isolation, based 
on the information provided on the clinical request forms and international guidelines for the 
diagnosis of UTIs) and that were positive for the nitrite and leukocyte-esterase tests were included in 
the data analysis [39]. Only the first isolate per patient was included in the study; however, isolates 
with different antibiotic-susceptibility patterns from the same patient were considered as different 
individual isolates. For the purpose of the statistical comparisons, the origin (inpatient vs. 
outpatient) of the positive samples were also recorded. The study was deemed exempt from ethics 
review by the Institutional Review Board as no patient data was recorded and data anonymity was 
maintained. 
2.2. Identification of Isolates During the Study Period 
Ten microliters of each uncentrifuged urine sample was cultured on UriSelect chromogenic 
agar (Bio-Rad, Berkeley, CA, USA), blood agar (bioMérieux, Marcy-l’Étoile, Lyon, France) and 
eosin-methylene blue agar (EMB; Bio-Rad, Berkeley, CA, USA) plates with a calibrated loop, 
according to the manufacturer’s instructions; the plates were incubated at 37 °C for 24–48 h, 
aerobically [39]. In the first part of the study period (2008–2012), presumptive, biochemical 
reaction-based methods and VITEK 2 Compact ID/AST (bioMérieux, Marcy-l’Étoile, France) were 
used for bacterial identification. Starting from 2013, matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) was introduced to the workflow of the Institute 
of Clinical Microbiology. Mass spectrometry was performed by the microFlex LT MALDI Biotyper 
(Bruker Daltonics, Bremen, Germany) instrument, using the MALDI Biotyper RTC 3.1 software 
(Bruker Daltonics, Bremen, Germany) and MALDI Biotyper Library 3.1 for the spectrum analysis. 
Life 2020, 10, 16 4 of 17 
 
The sample preparation procedure, methodology, and the technical details of the MALDI-TOF MS 
measurements were described elsewhere [39]. 
2.3. Susceptibility Testing of Relevant Isolates 
Antimicrobial susceptibility testing for the relevant Gram-negative bacterial isolates were 
performed based on the methodological recommendations and standards of the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) valid at the time of the interpretation; 
the Kirby–Bauer disk diffusion method (Liofilchem, Abruzzo, Italy), and E-test strips (in case of 
fosfomycin susceptibility testing; Liofilchem, Abruzzo, Italy) on Mueller–Hinton agar (MHA) plates, 
in addition, broth microdilution in a cation-adjusted Mueller–Hinton broth (in case of colistin 
susceptibility testing; MERLIN Diagnostik) was also used. For the verification of discrepant results, 
the VITEK 2 Compact ID/AST (bioMérieux, Marcy-l’Étoile, France) was used. Susceptibility testing 
included all relevant antibiotics for the respective bacteria, to allow for their classification into 
resistance categories based on the criteria detailed in Section 2.4; an antibiotic was not tested and 
was excluded from the analysis if intrinsic resistance was present, based on the EUCAST Expert 
Rules on Intrinsic Resistance and Exceptional Phenotypes [43]. To allow for easier data analysis, the 
bacterial isolates were grouped in six separate groups as follows, based on their similarities in 
intrinsic resistance: E. coli, Klebsiella spp., Citrobacter-Enterobacter-Serratia spp., 
Proteus-Providencia-Morganella spp., Pseudomonas aeruginosa and Acinetobacter spp., respectively 
[20,38–41]. The interpretation of susceptibility results was performed based on EUCAST breakpoints 
valid at the time of the interpretation. Intermediate results were grouped with and reported as 
resistant. The following strains were used as quality control (QC): S. aureus ATCC 29213, E. faecalis 
ATCC 29212, P. mirabilis ATCC 35659, E. coli ATCC 25922, P. aeruginosa ATCC 27853, A. baumannii 
ATCC 19606 and S. maltophilia ATCC 13637.  
2.4. Classification of Isolates into Resistance Categories 
During data analysis, respective isolates were classified into various resistance categories. 
Isolates were considered Wt/susceptible if they were susceptible to all tested antibiotics, excluding 
those where intrinsic non-susceptibility is present. Isolates were classified in the usual drug 
resistance (UDR; defined by McDonell et al. [30]) category, if they were resistant to at least one tested 
antibiotic outside of their realm of intrinsic non-susceptibility. Classification of the isolates as 
multidrug resistant (MDR; defined as acquired non-susceptibility to at least one agent in three or 
more antimicrobial categories), extensively drug resistant (XDR; bacterial isolates remain susceptible 
to only one or two antibiotic categories) and pandrug-resistant (PDR; non-susceptibility to all agents 
in all antimicrobial categories) was based on the CDC/ECDC recommendations [23]. The designation 
of difficult-to-treat resistance (DTR; defined by Kadri et al. [24]) was used if an isolate showed 
resistance to carbapenems (imipenem, meropenem and ertapenem/doripenem), extended-spectrum 
cephalosporins (the ones relevant for respective pathogens) and fluoroquinolones (ciprofloxacin, 
levofloxacin and moxifloxacin) [24]. Modified difficult-to-treat resistance (mDTR; introduced in this 
study, relevant in all bacterial categories, except for P. aeruginosa) was used if an isolate showed 
resistance to extended-spectrum cephalosporins (the ones relevant for respective pathogens) and 
fluoroquinolones (ciprofloxacin, levofloxacin and moxifloxacin), fosfomycin (for Enterobacterales 
isolates) and sulfamethoxazole-trimethoprim (for Enterobacterales and Acinetobacter spp.). For E. coli 
only, an additional category (mcDTR; modified difficult-to-treat resistance in E. coli) was also 
introduced, which includes susceptibility data for nitrofurantoin as well.  
As a part of this study, a predictive composite score was also introduced (pMAR), which is an 
augmented version of the multiple antibiotic resistance (MAR) index described previously [28,29], 
based on the formula (1) below, where nMDR is the number of MDR isolates in the respective category 
(e.g., E. coli, Citrobacter-Enterobacter-Serratia), ABMDR is the minimum number of antibiotics needed 
for the respective bacterial group to become MDR, nall is the number of all isolates in the respective 
group and ABall is the number of all antibiotics tested. The pMAR value corresponds to the 
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percentage chance (0%–100%) that the isolated pathogen in the present clinical situation will not be 
treatable by first-line antibiotics, based on local epidemiological characteristics. 
pMAR= 𝒏𝑴𝑫𝑹×𝑨𝑩𝑴𝑫𝑹𝒏𝒂𝒍𝒍× 𝑨𝑩𝒂𝒍𝒍 × 𝟏𝟎𝟎 [%] (1) 
2.5. Statistical Analyses 
Statistical analyses, including the descriptive analysis and statistical tests (Student’s t-test and 
Mann–Whitney U test) were performed with the SPSS software version 24 (IBM SPSS Statistics for 
Windows 24.0, IBM Corp., Armonk, NY, USA). The normality of variables was tested using Shapiro–
Wilk tests. A correlation analysis was also performed with the aim of assessing the temporal nature 
of changes in the ratio of UDR isolates during the study period; the coefficient of determination (R2) 
was also calculated. These analyses were performed using the Past 3.16 statistical software 
(Paleontological Museum, University of Oslo; Oslo, Norway). p values <0.05 were considered 
statistically significant. 
3. Results 
During the 10-year study period (1 January 2008–31 December 2017), the study site has received 
21,150 urine samples from outpatient clinics and 19,325 samples from inpatient departments that 
turned out to be positive for a significant urinary pathogen. Out of these isolates, n = 16,240 (76.8%) 
of outpatient isolates and n = 13,386 (69.3%) of inpatient isolates were Gram-negative bacteria 
relevant to our analyses (p = 0.038). The distribution of isolates is presented in Table 1. 
Table 1. Distribution of pathogens from urinary tract infections in our local setting (Albert 
Szent-Györgyi Clinical Center; Szeged, Hungary) between 2008 and 2017. 
Bacterial Isolates Outpatients  Inpatients 
Citrobacter-Enterobacter-Serratia 2.6% (n = 554) 3.0% (n = 578) 
Acinetobacter spp. 0.7% (n = 143) 0.7% (n = 133) 
Pseudomonas aeruginosa 2.8% (n = 588) 5.7% (n = 1096) 
Proteus-Providencia-Morganella 5.0% (n = 1058) 7.2% (n = 1392) 
Klebsiella spp. 8.9% (n = 1895) 13.4% (n = 2592) 
Gram-positive cocci 20.7% 20.7% 
Escherichia coli 56.8% (n = 12002) 42.3% (n = 8173) 
Candida spp. 0.4% 6.0% 
Other 2.1% 1.0% 
Values in boldface represent isolates included in our analysis. 
The classification of respective Gram-negative urinary isolates into the resistance categories 
defined in Section 4 is presented in Figures 1–6 (the differences in resistance categories among 
inpatient and outpatient isolates are presented in Supplementary Tables S1–S6), while the temporal 
trends associated with the prevalence of UDR isolates over the 10-year study period is presented in 
Figures 7–12, respectively. Out of the Enterobacterales isolates groups surveyed, members of the 
Citrobacter-Enterobacter-Serratia (CES) had the highest level of UDR isolates (88.9%; and 
consequently, the lowest number of wild-type isolates; Figures 3 and 9), while among NFGNB, 
Acinetobacter spp. had high levels of UDR (71.5%; Figures 6 and 12). mDTR levels were highest in the 
Proteus-Providencia-Morganella group (18.6%; Figure 4); the comparison between Acinetobacter 
(16.9%) and P. aeruginosa is not possible, as mDTR was not interpreted in that group. MDR levels in 
Acinetobacter spp. and P. aeruginosa species were the highest (9.7% and 8.5%, respectively) overall, 
while among Enterobacterales, high levels of MDR were seen in Proteus-Providencia-Morganella (9.1%) 
and Citrobacter-Enterobacter-Serratia (5.9%) (Figures 3–6.). Levels of DTR were 5-850 times higher in 
NFGNB than other Gram-negative isolates (7.3% and 16.9% vs. 0.02%–1.5%, respectively). 
XDR-levels were very low for E. coli, Proteus-Providencia-Morganella, Klebsiella spp., and CES isolates 
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(0%, 0%, 0.1% and 0.1%, respectively; Figures 1–4.). Very few isolates were resistant to colistin (n = 0 
in Enterobacterales, n = 24 for Acinetobacter spp. and n = 27 for P. aeruginosa) throughout the 10-year 
study period, however, all of these isolates were susceptible to at least one other agent, therefore, no 
PDR isolates were detected in any bacterial groups overall (Figures 1–6.). 
The prevalence of UDR isolates for E. coli was lowest in 2013 (Figure 7), for Klebsiella spp. in 2017 
(Figure 8), for Citrobacter-Enterobacter-Serratia in 2017 (Figure 9), for Proteus-Providencia-Morganella in 
2009 (Figure 10), for P. aeruginosa in 2013 and 2014 (Figure 11) and for Acinetobacter spp. in 2014 
(Figure 12). Varying levels of decreasing tendencies in the levels of UDR isolates were seen over time 
in almost all isolate groups, except in case of inpatient samples of Klebsiella spp. and 
inpatient/outpatient samples of Proteus-Providencia-Morganella, where an increasing tendency was 
seen. However, statistically significant correlation over time was only observed in inpatient samples 
of E. coli (p = 0.049), inpatient samples of Proteus-Providencia-Morganella (p = 0.036) and outpatient 
samples of CES (p = 0.043). 
Based on the previous analysis of susceptibility data, pMAR values were calculated, suggesting 
the percentage chance that the isolates from the bacterial group will be resistant to first-line 
antibiotics (Table 2); values were ranging between 18.9% and 44.5%, respectively. The highest pMAR 
value was recorded for Proteus-Providencia-Morganella isolates (40.3%), while the lowest was seen for 
P. aeruginosa isolates (20.2%) overall. 
 
Figure 1. Classification of E. coli isolates from UTIs into resistance categories (2008–2017). Variation 
between inpatient and outpatient isolates is presented in Supplementary Table S1. 
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Figure 2. Classification of Klebsiella spp. isolates from UTIs into resistance categories (2008–2017). 
Variation between inpatient and outpatient isolates is presented in Supplementary Table S2. 
 
Figure 3. Classification of Citrobacter-Enterobacter-Serratia spp. isolates from UTIs into resistance 
categories (2008-2017). Variation between inpatient and outpatient isolates is presented in 
Supplementary Table S3. 
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Figure 4. Classification of Proteus-Providencia-Morganella spp. isolates from UTIs into resistance 
categories (2008–2017). Variation between inpatient and outpatient isolates is presented in 
Supplementary Table S4. 
 
Figure 5. Classification of Pseudomonas aeruginosa isolates from UTIs into resistance categories (2008–
2017). Variation between inpatient and outpatient isolates is presented in Supplementary Table S5. 
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Figure 6. Classification of Acinetobacter spp. isolates from UTIs into resistance categories (2008–2017). 
Variation between inpatient and outpatient isolates is presented in Supplementary Table S6. 
 
Figure 7. Changing trends of E. coli UDR isolates over the 10-year study period (2008–2017). Blue 
dashed line indicates isolates from outpatients, while red dashed line isolates from inpatients; R2: 
coefficient of determination; R2outpatients: 0.3671 (36.71%; not significant), R2inpatients: 0.414 (41.40%; p = 
0.049). 
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Figure 8. Changing trends of Klebsiella spp. UDR isolates over the 10-year study period (2008–2017). 
blue dashed line indicates isolates from outpatients, while red dashed line isolates from inpatients; 
R2: coefficient of determination. R2outpatients: 0.8564 (85.64%; p=0.012), R2inpatients: 0.0235 (2.35%; not 
significant). 
 
Figure 9. Changing trends of Citrobacter-Enterobacter-Serratia UDR isolates over the 10-year study 
period (2008-2017). Blue dashed line indicates isolates from outpatients, while red dashed line 
isolates from inpatients; R2: coefficient of determination. R2outpatients: 0.4617 (46.17%; p=0.043), R2inpatients: 
0.0483 (4.83%; not significant). 
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Figure 10. Changing trends of Proteus-Providencia-Morganella UDR isolates over the 10-year study 
period (2008–2017). Blue dashed line indicates isolates from outpatients, while red dashed line 
isolates from inpatients; R2: coefficient of determination. R2outpatients: 0.1617 (16.17%; not significant), 
R2inpatients: 0.5611 (56.11%; p = 0.036). 
 
Figure 11. Changing trends of Pseudomonas aeruginosa UDR isolates over the 10-year study period 
(2008-2017). Blue dashed line indicates isolates from outpatients, while red dashed line isolates from 
inpatients; R2: coefficient of determination. R2outpatients: 0.1313 (13.13%; not significant), R2inpatients: 0.0124 
(1.24%; not significant). 
Life 2020, 10, 16 12 of 17 
 
 
Figure 12. Changing trends of Acinetobacter spp. UDR isolates over the 10-year study period 
(2008-2017). Blue dashed line indicates isolates from outpatients, while red dashed line isolates from 
inpatients; R2: coefficient of determination. R2outpatients: 0.3176 (31.76%; not significant), R2inpatients: 0.2772 
(27.72%; not significant). 
Table 2. pMAR values corresponding to respective urinary pathogens in the study period (2008–
2017). 
Bacterial Group Outpatients  Inpatients Overall 
Citrobacter-Enterobacter-Serratia 37.9% 38.2% 38.1% 
Acinetobacter spp. 27.1% 44.5% 35.7% 
P. aeruginosa 18.9% 21.3% 20.2% 
Proteus-Providencia-Morganella 37.6% 42.6% 40.3% 
Klebsiella spp. 30.3% 29.5% 29.9% 
E. coli 25.3% 27.7% 26.1% 
4. Discussion 
In the present study, 10-years’ worth of microbiological and resistance data for Gram-negative 
UTIs in Hungary were assessed, in light of existing and novel resistance classifications [24,28,30]. 
The surveillance of the etiology and susceptibility patterns in UTIs allow for targeted stewardship 
interventions in various healthcare facilities [37,44–46]. Resistance in Gram-negative bacteria has 
become one of the main concerns of clinicians (especially since the 2000s) [6]; in addition, 
plasmid-mediated resistance to carbapenems and colistin in Enterobacterales and non-fermenters 
may lead to widespread dissemination of pathogens with very few treatment options left [17,47–49]. 
Although the severity and mortality rate of UTIs (compared to invasive infections) is less 
pronounced, the economic burden of drug resistant urinary tract infections is significant, especially 
if these patients need to be hospitalized [32]. Therefore, the data presented herein may be useful for 
experts in clinical microbiology, epidemiology and public health, both in Hungary and on the 
International scene to highlight that growing levels of resistance is a severe issue in the context of 
UTIs, in outpatients and inpatients alike. Besides the “classical” drug resistance classifications 
(MDR-XDR-PDR), novel resistance categories found in the literature, and not used before in the 
context of UTIs (namely UDR and DTR) were also included [24,29,30]. In addition to these, our aim 
was to further the number of these resistance criteria with additional choices (mDTR, mcDTR and a 
predictive pMAR score) relevant in the classification of UTI pathogens.  
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In the report by Kadri et al. [24], the analysis of 46,521 isolates from bloodstream infections 
(originating from 173 US hospitals) were performed, pertaining to a four-year study period (2009–
2013): in their study, n = 471 (1.0%) of isolates were DTR overall, with significant variation among 
different species (E. coli: 0.04%, Klebsiella spp.: 1.7%, Enterobacter spp.: 0.6%, P. aeruginosa: 2.3% and A. 
baumannii: 18.3%). In our study, UDR isolates were the most common in most cases; this 
classification describes isolates that are not wild-type (i.e., fully susceptible) strains, but their therapy 
is manageable with standard agents. The case behind DTR (non-susceptibility to all first-line agents, 
based on Kadri et al. [24]) was that in case of these isolates, resistance is present against all agents 
with high efficacy, safety and low-toxicity (namely broad-spectrum cephalosporins, 
fluoroquinolones and carbapenems) and clinicians are forced to use other antibiotics with more 
disadvantageous or limited pharmacological properties, e.g., aminoglycosides (nephrotoxicity, 
ototoxicity, neurotoxicity, poor penetration into several anatomical sites), tetracyclines (especially 
tigecycline in case of drug resistant infections; low serum levels and black-box warning for increased 
mortality levels), colistin (nephrotoxicity, neurotoxicity, difficulties with formulations and dosing, 
poor penetration into several anatomical sites) [6,24,50,51]. Nonetheless, resistance to these 
“reserve” antibiotics should also be monitored to ascertain their clinical utility; for example, based 
on our previous reports, the levels of aminoglycoside resistance (gentamicin) in UTIs for E. coli was 
between 5% and 15%, 18% and 25% for Klebsiella spp., 8% and 25% for CES pathogens, 17% and 20% 
in Proteus-Providencia-Morganella, 31% and 47% for P. aeruginosa and 7% and 59% for Acinetobacter 
spp. [20,38–41], while colistin resistance was <1% in all respective groups, demonstrated in this 
study. The introduction of mDTR and mcDTR was also indicated, because in many institutions, 
carbapenem-sparing antimicrobial stewardship regimens are enforced to ensure low levels of 
resistance against these agents, when they are truly needed [52]. Thus, instead of carbapenems, 
sulfamethoxazole-trimethoprim and fosfomycin resistance (in addition to nitrofurantoin in case of 
mcDTR) were taken into consideration, as these are all drugs used as first-line antibiotics in the 
therapy of urinary tract infections [53,54].  
Classical resistance classifications (MDR-XDR-PDR) are very useful for epidemiological 
purposes; however, they may not correlate well with clinical outcomes [24–27,30,31]. Although 
several international bodies have published estimates on the excess mortality of MDR infections in 
Europe [55] and the US [56], these projections have been made based on predictive mathematical 
models, the relevance of which have been questioned by several reports [57,58]. Likewise, reports 
published on PDR infections have highlighted that clinical outcomes in their cases was not 
necessarily associated with the PDR status of the pathogens [59,60]. The category of MDR may be a 
source of discrepancies; for example, an extended-spectrum β-lactamase-producing and 
fluoroquinolone-resistant E. coli isolate may still be readily treated with fosfomycin. Similarly, 
ampicillin/sulbactam may still be effective highly resistant A. baumannii isolate; both of the 
mentioned agents are safe and effective alternative [24,39,40]. Another difficulty may stem from the 
large number of agents (may be as high as 15–17) that need to be tested to verify the XDR/PDR status 
of an isolate, which is usually not performed in most clinical laboratories [43]; this may lead to the 
reporting of erroneous results [24]. The latter is further complicated by the introduction of novel 
antibiotics (e.g., ceftolozane/tazobactam, ceftazidime/avibactam, eravacycline, 
delafloxacin-meglumine) into the routine susceptibility-testing platforms [16,24]. For the reasons 
mentioned above, in addition to its clinically-centered philosophy, introduction of DTR (and its 
modifications detailed in this study) to the bedside and in the clinical practice will definitely lead to 
substantial benefits in the assessment of the significance of bacterial resistance in human 
therapeutics [24]. The more frequent application of DTR (and m(c)DTR) by more 
healthcare-providers and in more published studies (preferably in correlation with clinical data) will 
lead to its wider recognition. 
Abbreviations: CDC: Centers for Disease Control and Prevention; CES: Citrobacter-Enterobacter-Serratia; CFU: 
colony-forming units; DTR: difficult-to-treat resistance; ECDC: European Centers for Disease Control and 
Prevention; EMB: eosine-methylene blue; EUCAST: European Committee on Antimicrobial Susceptibility 
Testing; ID: identification; LIS: laboratory information system; MALDI-TOF MS: matrix-assisted laser 
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desorption/ionization time-of-flight mass spectrometry; MAR: Multiple antibiotic resistance index; mDTR: 
modified difficult-to-treat resistance; mcDTR: modified difficult-to-treat resistance for Escherichia coli; MDR: 
multidrug-resistance; MHA: Mueller–Hinton agar; n.s.: not significant; ND4BB: New Drugs 4 Bad Bugs; 
NFGNB: non-fermenting Gram-negative bacteria; pMAR: a predictive composite score; PDR: pandrug 
resistance; R2: coefficient of determination; QC: quality control; QoL: quality of life; SXT: 
sulfamethoxazole-trimethoprim; UDR: usual drug resistance; UTI: urinary tract infection; Wt: wild-type; XDR: 
extensive drug resistance 
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